Chair Fred Lublin, MD, FAAN, FANA Saunders Family Professor of Neurology Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis Co-Chief Editor, Multiple Sclerosis and Related Disorders Icahn School of Medicine at Mount Sinai New York, NY
Faculty Bryan Walker, MHS, PA-C Assistant Professor Associate Director, Didactic Curriculum The George Washington University School of Medicine and Health Science Physician Assistant Program Washington, DC
AMA PRA Category 1 Credit TM
Multiple sclerosis is a chronic neurologic disorder with potential for substantial negative impact on quality of life. Treatment seeks to return function after an attack, prevent new attacks, limit disability progression, and improve quality of life. The management of MS is complex because of the variability in the clinical course for each patient, emerging therapies, and patient characteristics and preferences. A lack of knowledge about individualized therapy, available and emerging therapies, and clinician-patient relationships can result in suboptimal therapeutic outcomes among patients with MS.
. Target Audience
This activity is intended for physicians, PAs, and NPs specializing in neurology or MS.
Upon completion of this educational activity, the participant should be able to:
Develop first- and second-line disease-modifying treatment regimens for patients with relapsing-remitting MS based on the latest clinical trial evidence.
Appropriately monitor response to MS disease-modifying therapy to determine when an adjustment to therapy is needed during the course of the disease.
Provide appropriate care and counsel for patients and their families.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Fred Lublin, MD, FAAN, FANA has disclosed the following:
Research Funding: Acorda Therapeutics, Inc., Biogen Idec, Novartis Pharmaceuticals Corp, Teva Neuroscience, Inc., Genzyme, Sanofi, Celgene, Transparency Life Sciences, NIH, NMSS
Advisory Board: Bayer HealthCare Pharmaceuticals, Biogen Idec, EMD Serono, Inc., Novartis, Teva Neuroscience, Actelion, Sanofi-Aventis, Acorda, Questcor, Roche, Genentech, Celgene, Johnson & Johnson, Revalesio, Coronado Bioscience, Genzyme, MedImmune, Bristol-Myers Squibb, Xenoport, Receptos, Forward Pharma, to-BBB technologies
Stock Ownership: Cognition Pharmaceuticals, Inc.
Bryan Walker, MHS, PA-C has disclosed the following:
Stock Ownership: Biogen Idec
Penn State staff involved in the development and review of this activity have nothing to disclose.
Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling. Credit Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5656-15-T.
Credit is awarded to participants who score 80% or better on the post-test.
The online activity will take approximately 30 minutes to complete. Commercial Support Statements
Supported by independent educational grants from Teva Pharmaceuticals and Novartis Pharmaceuticals Corporation.
There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, Teva, or Novartis. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.